Table 2.

Clinical Findings and Treatment Data of Patients with the Inflammatory Bowel Disease-associated Aseptic Abscesses from the Literature Database and Our Reported Case.

Reference/Number of patients	Total. 1994 to 2020 [1, 6-8, our case] /43
Age/sex	Mean 29.7, range10-80/27F&16M
IBD phenotype (CD/UC/IC)	29CD/13UC/1IC
Age of IBD diagnosis/temporal relation to diagnosis of AA	Average age of IBD onset=25.4 (range10-72, 3unknown)/before (n=23), concomitant (n=11), after (n=9)
IBD flare during AA	Yes(n=20), no(n=23)
Symptoms	Fever(n=36), abdominal pain(n=30), weight loss(n=16), diarrhea(n=14)
Location of AA	Spleen(n=21), liver(n=9), lymph nodes(n=13), muscles(n=2), sternum(n=2), epidural(n=2), and eyelids, pancreas, kidney, pharynx, scalp, face, inner canthus, submaxilla, chest, forearm, nasal septum(n=1, respectively)
Other EIM of IBD	Arthritis(n=10), myalgia(n=5), neutrophilic dermatosis(n=2), PG(n=4), sweet’s syndrome(n=2), aphthous ulcer(n=8), and abscesses of his lower legs with caseating granulomas, panniculitis, polyneuropathy(n=1, respectively)
Antibiotic treatment	Yes(n=39), no(n=4)
Corticosteroids	Yes(n=39), no(n=4)
Additional immunotherapy	Total(n=18), cyclophosphamide(n=3), azathioprine(n=12), methotrexate(n=1), GCAP(n=1), adalimumab(n=1), infliximab(n=5)
Surgical procedures	Splenectomy(n=17), incision and drainage(n=5), laparoscopic biopsy of mesenteric lymph nodes(n=1)
Maintenance therapy after diagnosis of AA	Information not provided(n=30), prednisone(n=4), azathioprine(n=2), sulfasalazine(n=1), 5-ASA(n=3), adalimumab(n=1), infliximab(n=4)
Number of relapses	Mean 1.02, range0-5(n=34)

AA: aseptic abscess, CD: Crohn’s disease, EIM: extraintestinal manifestation, F: female, GCAP: granulocytapheresis, IC: indeterminate colitis, IBD: inflammatory bowel disease, M: male, PG: pyoderma gangrenosum, UC: ulcerative colitis